Clinical Trials Logo

Graft vs Host Disease clinical trials

View clinical trials related to Graft vs Host Disease.

Filter by:

NCT ID: NCT04745637 Available - Clinical trials for Primary Myelofibrosis (PMF)

Managed Access Programs for INC424, Ruxolitinib

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib

NCT ID: NCT04745221 Recruiting - Clinical trials for Graft Versus Host Disease, Acute

Efficacy and Safety of Auto-FMT in Preventing aGVHD

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

To evaluation the efficacy and safety of autologous fecal bacteria transplantation in preventing acute graft versus host disease after haploidentical hematopoietic stem cell transplantation. Bone marrow transplant patients were recruited.

NCT ID: NCT04744116 Recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

Start date: February 17, 2021
Phase: Early Phase 1
Study type: Interventional

This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients with acute graft versus host disease that does not respond to steroid therapy (steroid-refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. cb-MSCs are a type of tissue helper cell that can be removed from donated umbilical cord blood tissue and grown into many different cell types that can be used to treat cancer and other disease, such as graft versus host disease. This trial aims to learn if adding cb-MSCs to ruxolitinib may help control steroid-refractory acute graft versus host disease.

NCT ID: NCT04738981 Completed - Clinical trials for Graft Vs Host Disease

Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT

Start date: February 1, 2021
Phase: Phase 3
Study type: Interventional

Randomized, open-label, multicenter study to investigate the efficacy and safety of umbilical cord-derived mesenchymal stem cells (UC-MSC) for the treatment of steroid-resistant acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a view to establishing an effective treatment protocol for steroid-resistant aGVHD.

NCT ID: NCT04728646 Withdrawn - Clinical trials for Graft Vs Host Disease

Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes

Start date: September 2021
Phase: Phase 4
Study type: Interventional

To evaluate the safety and efficacy of Dextenza intracanalicular insert in patients with ocular graft-versus-host disease (GVHD).

NCT ID: NCT04716075 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

ACALLO
Start date: August 19, 2019
Phase: Phase 2
Study type: Interventional

In this phase II multicenter trial we plan to use acalabrutinib before and after allogeneic hematopoietic stem cell transplantation (alloSCT) with reduced intensity conditioning (RIC) in patients with refractory/relapsed MCL and CLL with poor prognostic factors. Acalabrutinib will be used before alloSCT with the intention to reduce tumor burden and after transplant to augment disease control.

NCT ID: NCT04711967 Recruiting - Clinical trials for Acute Graft Versus Host Disease in Intestine

Prospective Study of FMT for Acute Intestinal GVHD After Allo-HSCT

Start date: March 10, 2021
Phase: N/A
Study type: Interventional

Acute intestinal GVHD is the main cause of death after allo-HSCT, and FMT is a new treatment method for this disease. In this prospective study, the investigators will recruit intestinal GVHD patients to demonstrate the efficacy and safety of FMT.

NCT ID: NCT04710576 Active, not recruiting - Clinical trials for Chronic Graft-versus-host-disease

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

AGAVE-201
Start date: March 4, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.

NCT ID: NCT04692376 Recruiting - Clinical trials for Chronic Graft-versus-host Disease

MSC for Treatment of cGVHD After Allo-HSCT

Start date: January 10, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of mesenchymal stem cells in patients with chronic graft-versus-host disease.

NCT ID: NCT04688021 Recruiting - Leukemia Clinical Trials

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Start date: December 3, 2020
Phase: Phase 2
Study type: Interventional

A single-arm trial using Tocilizumab for acute GVHD prophylaxis after haploidentical HSCT.